MedTrace Logo

Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

NCT00188084 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2005-10-28

No results posted yet for this study

Summary

Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:

1. A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
2. The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.

The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival.

Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.

Conditions

  • Adult Acute Lymphoblastic Leukemia

Interventions

PROCEDURE

DNA Index

PROCEDURE

S-Phase%

PROCEDURE

CD45 expression

PROCEDURE

P16 metabolic way

Sponsors & Collaborators

  • French Innovative Leukemia Organisation

    collaborator OTHER

  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Laurence M Baranger, MD · University Hospital, Angers

Eligibility

Min Age
15 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2005-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00188084 on ClinicalTrials.gov